Targeted catalytic hair lightening via yeast particle delivery system
An innovative hair lightening technology using yeast particles for targeted delivery of catalysts to the hair cortex. This method enhances peroxide efficiency, minimizes keratin damage, and allows fragrance encapsulation to mask odors, offering a safer cosmetic solution.
Overview
This targeted catalytic hair lightening system employs yeast particles (YPs) to achieve salon-grade hair lightening at neutral pH with minimal hydrogen peroxide. The YPs are designed to bind to hair cuticles, ensuring the precise release of lightening catalysts directly into the hair cortex. This approach enhances the effectiveness of low-dose peroxide by localizing radical production where melanin resides, reducing potential keratin damage. Additionally, the technology allows for the encapsulation of fragrances to mask oxidative odors, making it a user-friendly cosmetic solution.
Technical specifications
- Yeast Particle Technology: Utilizes YPs modified with hair-binding ligands for targeted delivery.
- Encapsulation: YP cavities encapsulate hair lightening catalysts and fragrances, embedded in a storage matrix to prevent premature activation.
- Activation Mechanism: Upon mixing with a low peroxide developer, the matrix hydrates YPs, converting the catalysts into their active form for targeted release.
- Catalysts: Includes iron gluconate and gallic acid, optimized for efficient peroxide activation and localized release.
- Fragrance Encapsulation: Co-encapsulation of fragrances is possible to mask oxidative odors.
Technology readiness level
The technology is currently at TRL 3, indicating that active research and laboratory validation are underway. Future validation will focus on encapsulation efficiency, release kinetics, and stability, with comparisons to benchmark catalysts.
About University of Massachusetts Medical School
A public academic health sciences center within the University of Massachusetts system, it combines medical education, graduate training, and patient care with a strong research enterprise. Close integration with a major hospital system enables access to diverse patient populations, clinical data, and translational infrastructure, supporting industry‑sponsored studies and real‑world evaluation. Co‑located research core facilities and centralized contracting, IRB, and compliance support streamline collaboration, from early discovery through multicenter trials. The institution attracts significant NIH funding and competitive awards from other federal agencies and foundations. A dedicated technology transfer office manages IP, material transfer and licensing, and supports startup formation and corporate research agreements.
Inquire about this partnering listing
Industry applications
delivered to your inbox.